Is INZY undervalued or overvalued?
As of 2025-03-21, the Intrinsic Value of Inozyme Pharma Inc (INZY) is -7.94 USD. This INZY valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.95 USD, the upside of Inozyme Pharma Inc is -931.85%. This means that INZY is overvalued by 931.85%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -7.94 - -7.94 | -7.94 | -931.85% |
| P/E | (19.22) - (24.30) | (19.42) | -2133.9% |
| DDM - Stable | (10.22) - (27.18) | (18.70) | -2058.9% |
| DDM - Multi | (0.15) - (0.31) | (0.20) | -121.2% |
| Market Cap (mil) | 61.32 |
| Beta | 1.75 |
| Outstanding shares (mil) | 64.24 |
| Enterprise Value (mil) | 86.20 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.07% |
| Cost of Debt | 5.00% |
| WACC | 8.62% |